Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CTNM
stocks logo

CTNM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.356
-36.43%
--
--
-0.633
+2.15%
--
--
-0.623
+0.54%
Estimates Revision
The market is revising Downward the revenue expectations for Contineum Therapeutics, Inc. (CTNM) for FY2025, with the revenue forecasts being adjusted by -16.67% over the past three months. During the same period, the stock price has changed by -5.87%.
Revenue Estimates for FY2025
Revise Downward
down Image
-16.67%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.13%
In Past 3 Month
Stock Price
Go Down
down Image
-5.87%
In Past 3 Month
Wall Street analysts forecast CTNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTNM is 24.00 USD with a low forecast of 20.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast CTNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTNM is 24.00 USD with a low forecast of 20.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.630
sliders
Low
20.00
Averages
24.00
High
29.00
Current: 11.630
sliders
Low
20.00
Averages
24.00
High
29.00
Baird
Outperform
to
NULL
downgrade
$16 -> $14
2025-11-24
Reason
Baird
Price Target
$16 -> $14
2025-11-24
downgrade
Outperform
to
NULL
Reason
Baird lowered the firm's price target on Contineum to $14 from $16 and keeps an Outperform rating on the shares. The firm updated its model following the announcement of the unfortunate trial miss for PIPE-307 RRMS however, the core thesis for 2026 remains unchanged.
RBC Capital
Brian Abrahams
Outperform
to
NULL
downgrade
$25 -> $22
2025-11-21
Reason
RBC Capital
Brian Abrahams
Price Target
$25 -> $22
2025-11-21
downgrade
Outperform
to
NULL
Reason
RBC Capital analyst Brian Abrahams lowered the firm's price target on Contineum to $22 from $25 but keeps an Outperform rating on the shares. The company reported that the phase 2 rrMS VISTA study of M1 antagonist PIPE-307 did not meet its primary or secondary endpoints, but while this removes the potential for upside optionality, the firm had always viewed this trial and indication as high risk, the analyst tells investors in a research note. RBC adds that the decision should not meaningfully impact the potential for '307's success in depression, and the program's core valuation remains predicated on their other asset '791's promise in IPF, or idiopathic pulmonary fibrosis.
Leerink
initiated
$20
2025-09-25
Reason
Leerink
Price Target
$20
2025-09-25
initiated
Reason
Leerink initiated coverage of Contineum with an Outperform rating and $20 price target.
William Blair
analyst
Outperform
initiated
$23.26
2025-06-19
Reason
William Blair
analyst
Price Target
$23.26
2025-06-19
initiated
Outperform
Reason
William Blair initiated coverage of Contineum with an Outperform rating. Contineum is a clinical-stage biotech developing small-molecule therapeutics for indications in the neuroinflammation and immunology space developing PIPE-791, a wholly owned asset for the treatment of idiopathic pulmonary fibrosis, progressive forms of multiple sclerosis and chronic pain indications, notes the analyst, who sees a fair value of $23.26 per share.
Jones Trading
Debanjana Chatterjee
Strong Buy
Initiates
$23
2025-03-13
Reason
Jones Trading
Debanjana Chatterjee
Price Target
$23
2025-03-13
Initiates
Strong Buy
Reason
Morgan Stanley
Jeffrey Hung
Buy
Initiates
$25
2025-03-07
Reason
Morgan Stanley
Jeffrey Hung
Price Target
$25
2025-03-07
Initiates
Buy
Reason
Morgan Stanley assumed coverage of Contineum with an Overweight rating. The firm believes PIPE-791 is competitive in idiopathic pulmonary fibrosis given its optimized pharmacokinetics and for PIPE-791 for primary progressive multiple sclerosis it believes Phase 1b topline results in Q2 can de-risk the Phase 2 study, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Contineum Therapeutics Inc (CTNM.O) is -6.23, compared to its 5-year average forward P/E of -6.65. For a more detailed relative valuation and DCF analysis to assess Contineum Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.65
Current PE
-6.23
Overvalued PE
-3.22
Undervalued PE
-10.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.80
Undervalued EV/EBITDA
-8.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
51.46
Current PS
0.00
Overvalued PS
81.62
Undervalued PS
21.30
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CTNM News & Events

Events Timeline

(ET)
2025-12-12
02:00:00
Goldman Sachs Increases Offering Size to $90M
select
2025-12-11 (ET)
2025-12-11
16:40:00
Goldman Sachs and Others Act as Joint Book-Running Managers for Proposed Offering
select
2025-11-20 (ET)
2025-11-20
16:09:09
Contineum Phase 2 VISTA trial fails to achieve primary and secondary objectives.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-12Newsfilter
PinnedContineum Therapeutics Launches $75 Million Public Offering
  • Offering Announcement: Contineum Therapeutics has initiated a public offering of $75 million aimed at funding its research in neuroscience, inflammation, and immunology, thereby enhancing its competitive position in the market.
  • Underwriter Option: The company intends to grant underwriters a 30-day option to purchase an additional $11.25 million in shares, which will further bolster its financing capabilities and support future R&D efforts.
  • Strong Underwriter Lineup: The involvement of Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets, and William Blair as joint book-running managers demonstrates significant market confidence and support for the company.
  • Market Uncertainty: The completion timing and size of the offering remain uncertain, reflecting the volatility of market conditions that could impact the company's future cash flow and project timelines.
[object Object]
Preview
8.5
12-12Newsfilter
Contineum Therapeutics Prices Upsized Offering of 7.35M Shares at $12.25, Raising $90M
  • Upsized Offering: Contineum Therapeutics has announced an upsized public offering of 7,346,938 shares of Class A common stock priced at $12.25 per share, expected to raise approximately $90 million, thereby strengthening the company's financial position to support its clinical-stage biopharmaceutical development.
  • Underwriter Selection: The offering is being managed by Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets, and William Blair, reflecting market confidence in Contineum and potentially enhancing its market position in the biopharmaceutical sector.
  • Additional Purchase Option: The company has granted underwriters a 30-day option to purchase up to an additional 1,102,040 shares at the same price, further enhancing financial flexibility and potentially providing additional funding for future research and development projects.
  • Expected Closing Date: The offering is anticipated to close on December 15, 2025, subject to customary closing conditions, which will provide the company with much-needed capital to advance its innovative therapies targeting neuroscience, inflammation, and immunology indications.
[object Object]
Preview
8.5
12-12Businesswire
Contineum Therapeutics Prices Upsized Offering of 7.35M Shares at $12.25, Raising $90M
  • Upsized Offering: Contineum Therapeutics announced the pricing of an upsized public offering of 7,346,938 shares of Class A common stock at $12.25 per share, raising approximately $90 million, which will enhance the company's financial capacity to support its R&D in biopharmaceuticals.
  • Underwriter Selection: The offering is managed by Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets, and William Blair, reflecting strong market confidence in the company's future and potentially attracting more investor interest.
  • Additional Purchase Option: The company granted underwriters a 30-day option to purchase an additional 1,102,040 shares at the same price, further enhancing financial flexibility and potentially providing additional funding for future R&D projects.
  • Expected Closing Date: The offering is expected to close on December 15, 2025, subject to customary closing conditions, and if successful, will provide crucial funding for the company's upcoming clinical trials and product development.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Contineum Therapeutics Inc (CTNM) stock price today?

The current price of CTNM is 11.63 USD — it has decreased -11.02 % in the last trading day.

arrow icon

What is Contineum Therapeutics Inc (CTNM)'s business?

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

arrow icon

What is the price predicton of CTNM Stock?

Wall Street analysts forecast CTNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTNM is 24.00 USD with a low forecast of 20.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Contineum Therapeutics Inc (CTNM)'s revenue for the last quarter?

Contineum Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Contineum Therapeutics Inc (CTNM)'s earnings per share (EPS) for the last quarter?

Contineum Therapeutics Inc. EPS for the last quarter amounts to -0.45 USD, increased 12.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Contineum Therapeutics Inc (CTNM)'s fundamentals?

The market is revising Downward the revenue expectations for Contineum Therapeutics, Inc. (CTNM) for FY2025, with the revenue forecasts being adjusted by -16.67% over the past three months. During the same period, the stock price has changed by -5.87%.
arrow icon

How many employees does Contineum Therapeutics Inc (CTNM). have?

Contineum Therapeutics Inc (CTNM) has 41 emplpoyees as of December 13 2025.

arrow icon

What is Contineum Therapeutics Inc (CTNM) market cap?

Today CTNM has the market capitalization of 339.39M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free